Sysmex Corporation has announced its acquisition of two German companies: Partec GmbH and Inostics GmbH. Sysmex is located in Kobe, Japan. Press release from Sysmex dated September 24, 2013.
Partec is a pioneering company in the field of flow cytometry (FCM). It has amassed significant expertise and development capabilities involving leading-edge FCM products. The company has gained a strong presence in emerging markets and developing countries for its efforts in such areas as HIV monitoring, malaria diagnostics and other infectious diseases. In developed countries, Partec provides testing instruments that employ its FCM technology, targeting research institutions and customers in general industry categories.
Inostics is a diagnostics service company providing molecular testing for individualized cancer patient management and drug development. The core competency of Inostics is centered around the detection of genetic changes, such as somatic mutations, in blood or tissue samples. The company currently serves the contract research and the clinical trials biomarker services market. Inostics was founded in September 2008
Under the share purchase agreements, Sysmex will acquire Partec’s flow cytometry (FCM) technology, which is advantageous for both research and diagnostics purposes and Inostics’s highly-sensitive digital polymerase chain reaction (dPCR) technology for circulating DNA analysis. In addition to establishing new analytical platforms by integrating both technologies, Sysmex will be entering the personalized medicine business leveraging its global sales and support network.